ST三圣(002742) - 2018 Q1 - 季度财报(更新)

Financial Performance - The company's operating revenue for Q1 2018 was ¥533,078,703.35, representing a 65.16% increase compared to ¥322,756,683.94 in the same period last year[8] - The net profit attributable to shareholders was ¥34,392,415.00, up 32.86% from ¥25,886,044.22 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥31,479,684.82, reflecting a 35.52% increase from ¥23,228,863.57 in the previous year[8] - Basic earnings per share increased to ¥0.08, a rise of 33.33% from ¥0.06 in the previous year[8] - The estimated net profit attributable to shareholders for the first half of 2018 is projected to be between 69.96 million and 94.66 million RMB, representing a decrease of 25.60% to 45.01% compared to the same period in 2017[18] - The decrease in net profit is attributed to the absence of non-recurring investment income from the acquisition of Chunrui Medical, which generated 64.04 million RMB in the same period last year[18] - Net profit for the quarter was ¥42,868,141.21, up from ¥26,614,969.13 year-over-year, reflecting a growth of approximately 61%[35] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a net outflow of ¥93,627,105.20, compared to a net inflow of ¥10,612,168.77 in the same period last year, marking a decrease of 982.26%[8] - The cash flow from operating activities showed a significant outflow, indicating potential challenges in operational efficiency[46] - The cash flow from investing activities showed a net outflow of CNY 56,347,067.75 in Q1 2018, compared to a net outflow of CNY 124,199,658.21 in Q1 2017[43] - The financing activities resulted in a net cash outflow of CNY 28,126,634.23 in Q1 2018, contrasting with a net inflow of CNY 72,378,397.33 in the same period last year[43] - The net cash flow from operating activities was -42,470,910.58 CNY, a significant decrease compared to 81,143,005.41 CNY in the previous year[46] - The total cash and cash equivalents at the end of Q1 2018 were CNY 64,745,179.09, down from CNY 153,375,495.10 at the end of Q1 2017[43] - The company experienced a net decrease in cash and cash equivalents of 148,123,199.60 CNY during the quarter[47] - The initial cash and cash equivalents balance was 173,583,164.90 CNY, highlighting a substantial decline by the end of the quarter[47] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,215,653,213.50, a slight decrease of 0.51% from ¥4,237,184,337.14 at the end of the previous year[8] - As of March 31, 2018, the total assets of the company amounted to 4.22 billion RMB, a slight decrease from 4.24 billion RMB at the beginning of the year[29] - The company's total liabilities as of March 31, 2018, were 2.54 billion RMB, down from 2.60 billion RMB at the beginning of the year[28] - The company’s total liabilities decreased to ¥2,173,486,998.33 from ¥2,234,568,887.71, a reduction of about 2.73%[32] - The net assets attributable to shareholders increased by 2.13% to ¥1,446,259,992.98 from ¥1,416,141,007.37 at the end of the previous year[8] Expenses - The company reported a significant increase in management expenses, which rose by 64.14% to ¥54,412,635.25, primarily due to increased costs associated with diversified and international development[15] - Financial expenses surged by 115.53% to ¥25,325,199.99, mainly due to increased bond interest expenses compared to the previous year[15] - Operating costs amounted to ¥487,112,213.65, compared to ¥292,400,770.26 in the prior period, indicating a rise in expenses[35] - The total operating expenses for Q1 2018 were CNY 186,359,907.67, up from CNY 163,623,572.25 in Q1 2017, indicating an increase of 13.8%[38] - The financial expenses for Q1 2018 rose sharply to CNY 25,446,059.32, compared to CNY 10,203,564.43 in the previous year, marking an increase of 149.8%[38] Shareholder Information - The company had a total of 52,879 common shareholders at the end of the reporting period[11] - The company is actively promoting its non-public offering of A-shares, with updates to be disclosed based on progress[16] - There were no instances of non-operating fund occupation by controlling shareholders or related parties during the reporting period[20] - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[17] Investments and Projects - The pharmaceutical project investment in Ethiopia is progressing smoothly, with equipment installation and debugging expected to lead to trial operations in the second half of the year[16]